Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term Debt
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed N.V (MYNZ) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Mainz Biomed N.V (MYNZ) over the last 1 years, with Jun 2025 value amounting to $9.8 million.

  • Mainz Biomed N.V's Liabilities and Shareholders Equity rose 15.96% to $9.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $46.9 million, marking a year-over-year decrease of 23.20%. This contributed to the annual value of $13.2 million for FY2024, which is 14.09% down from last year.
  • According to the latest figures from Q2 2025, Mainz Biomed N.V's Liabilities and Shareholders Equity is $9.8 million, which was down 25.95% from $13.2 million recorded in Q4 2024.
  • In the past 5 years, Mainz Biomed N.V's Liabilities and Shareholders Equity ranged from a high of $27.6 million in Q2 2022 and a low of $8.5 million during Q2 2024.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $15.4 million (2023), whereas its average is $14.8 million.
  • As far as peak fluctuations go, Mainz Biomed N.V's Liabilities and Shareholders Equity skyrocketed by 1,391.35% in 2021, and later tumbled by 56.21% in 2024.
  • Over the past 5 years, Mainz Biomed N.V's Liabilities and Shareholders Equity (Quarterly) stood at $10.0 million in 2021, then spiked by 101.59% to $20.2 million in 2022, then decreased by 23.87% to $15.4 million in 2023, then declined by 14.09% to $13.2 million in 2024, then climbed by 15.96% to $9.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $9.8 million in Q2 2025, compared to $13.2 million in Q4 2024 and $8.5 million in Q2 2024.